Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

Kristian Reich^*, Melinda Gooderham, Diamant Thaçi, Jeffrey J. Crowley, Caitriona Ryan, James G. Krueger, Tsen Fang Tsai, Mary Flack, Y. Gu, David A. Williams, Elizabeth H.Z. Thompson, C. Paul

^*Korrespondierende/r Autor/-in für diese Arbeit